Auteurs
Merge
Accueil
Racine
Merge
Exploration
Accueil
Racine
Accueil
Racine

Serveur d'exploration Tocilizumab - Merge (Accueil)

Index « Auteurs » - entrée « K. Shidara »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
K. Shi < K. Shidara < K. Shimizu  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
002F14 (2013) Y. Shimizu [Japon] ; E. Tanaka [Japon] ; E. Inoue [Japon] ; K. Shidara [Japon] ; D. Hoshi [Japon] ; N. Sugimoto [Japon] ; E. Sato [Japon] ; Y. Seto [Japon] ; S. Momohara [Japon] ; A. Nakajima [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]FRI0096 Influence of dose titration of concomitant steroid and methotrexate during biologic therapy on remission rates in patients with rheumatoid arthritis according to the new ACR/EULAR remission criteria in daily practice based on the iorra cohort
002F25 (2013) K. Shidara [Japon] ; A. Nakajima [Japon] ; E. Inoue [Japon] ; D. Hoshi [Japon] ; E. Tanaka [Japon] ; Y. Inoue [Japon] ; A. Kobayashi [Japon] ; Y. Seto [Japon] ; S. Momohara [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]FRI0068 Sustaining remission as defined by the new acr/eular criteria leads to better quality of life in patients with rheumatoid arthritis
002F28 (2013) K. Ochi [Japon] ; E. Tanaka [Japon] ; K. Shidara [Japon] ; K. Ikari [Japon] ; A. Nakajima [Japon] ; A. Taniguchi [Japon] ; S. Momohara [Japon] ; H. Yamanaka [Japon]FRI0065 Clinical factors associated with the progression of functional impairment in rheumatoid arthritis patients who maintained the remission criteria defined by the new acr/eular criteria
003144 (2013) E. Tanaka [Japon] ; E. Inoue [Japon] ; D. Hoshi [Japon] ; A. Kobayashi [Japon] ; N. Sugimoto [Japon] ; K. Shidara [Japon] ; E. Sato [Japon] ; Y. Seto [Japon] ; A. Nakajima [Japon] ; S. Momohara [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]AB0528 Cost-effectiveness of a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, tocilizumab, in rheumatoid arthritis using IORRA cohort database
003239 (2013) E. Tanaka [Japon] ; E. Inoue [Japon] ; D. Hoshi [Japon] ; K. Shidara [Japon] ; E. Sato [Japon] ; Y. Inoue [Japon] ; Y. Seto [Japon] ; A. Nakajima [Japon] ; S. Momohara [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]AB0308 Optimal timing for tocilizumab administration to patients with rheumatoid arthritis in japan based on a cost-effectiveness analysis using the iorra cohort study

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Merge

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i -k "K. Shidara" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i  \
                -Sk "K. Shidara" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Merge
   |type=    indexItem
   |index=    Author.i
   |clé=    K. Shidara
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021